Navigation Links
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
Date:7/6/2009

BRIDGEWATER, N.J., July 6 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the results of the long-term, 5-year study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in patients with type 2 diabetes, published on-line in Diabetologia (DOI 10.1007/s00125-009-1415-7) showed similar effects on retinopathy and overall safety in the two treatment groups. This is the longest controlled study ever reported using insulin glargine.

Diabetic retinopathy is a major cause of blindness in patients with diabetes. It is a progressive disease that results from cellular proliferation within the eye. The stimulation of IGF1 receptors is involved in this process. In the study of patients with retinopathy, the progression of diabetic retinopathy was similar in the two treatment groups over the long-term course of treatment.

This indicates that Lantus does not have mitogenic effects different from the human NPH insulin within the eye.

"This 5-year study is the longest randomized controlled study with insulin glargine versus NPH human insulin," said lead investigator Julio Rosenstock, MD, Director of the Dallas Diabetes and Endocrine Center at Medical City and also Clinical Professor of Medicine, University of Texas Southwestern Medical School. "This study demonstrated no evidence of a greater risk of progression of retinopathy with insulin glargine."

The 5-year open-label study was specifically designed to further characterize the retinal safety profile of Lantus(R) versus NPH in 1024 patients (Lantus(R) once daily: 515 patients; NPH twice daily: 509 patients). Retinopathy progression was assessed using serial fundus photography.
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
2. Clinical Data Demonstrates 5-Year Efficacy and Safety of Aquamid(R) in Facial Augmentation
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
10. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... percent of Americans believe the abuse of strong prescription pain ... safety issue in the United States , ... & Partners, a Cincinnati based research ... the prescription medication abuse problem and the need for medical ... facing our country," Rex Repass , CEO of the ...
(Date:8/21/2014)... InfinityQS International, Inc., the global authority ... today announces Infusion Chicago, its 9 th ... Oct. 9-10, 2014, at the Chicago Marriott Downtown ... necessity for implementing a quality system that optimizes ... gain insight into production processes. Complimentary registrations are ...
(Date:8/21/2014)... 2014 Professional Compounding Centers of America ... awarding the three best scientific presentations at the ... . The Formulating Better Medicines for Children ... Athens, Greece , includes dozens of ... from which three winners will be selected by ...
Breaking Medicine Technology:Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2
... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ... Administration (FDA) has accepted for review the Company,s supplemental ... Use for the prevention of gout flares in patients ... Fee Act (PDUFA), the goal for a standard review ...
... CITY, Nev., Nov. 22, 2011   Denali Concrete Management ... November 21, 2011 of the reverse acquisition of Denali ... of which Denali acquired all the outstanding shares of ... has been granted from Can-Fite an exclusive license over ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 2Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 3
(Date:8/21/2014)... HealthDay Reporter THURSDAY, Aug. ... in treating respiratory syncytial virus (RSV), a leading cause of ... major progress in being able to treat human RSV infections ... second only to influenza virus," said study author Dr. John ... College of Medicine in Memphis. "There is no ...
(Date:8/21/2014)... According to the new report “Waterborne Coatings ... PTFE, PVDF, PVDC, & Others), by Application (Architectural, ... & Others) - Global Forecast to 2019” published ... estimated to reach $77,838.71 Million by 2019. , ... spread through 225 Slides and in-depth TOC on ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 According to ... "Enteral Feeding Devices Market (Enteral Feeding Tubes, Enteral Feeding ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 ... valued at USD 2.0 billion in 2012 and is ... billion in 2019growing at a CAGR of 6.2% from ...
(Date:8/21/2014)... polio is considered nearly eradicated. Each year only a ... the University of Bonn, together with colleagues from Gabon, ... able to resist the vaccine protection to a considerable ... the Congo in 2010. The pathogen could also potentially ... now in the magazine PNAS . , The ...
(Date:8/21/2014)... One of the emerging trends that the Intranasal ... increasing adoption of non-invasive administration products. As non-invasive nasal ... their convenient application, they find more preference among end-users. ... used for the administration of drugs for the treatment ... such as allergic and non-allergic rhinitis and sinusitis. The ...
Breaking Medicine News(10 mins):Health News:New Drug May Fight Serious Respiratory Virus in Infants 2Health News:New Drug May Fight Serious Respiratory Virus in Infants 3Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 2Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 3Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 4Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Polio: Mutated virus breaches vaccine protection 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5
... 24 NHS Choices ( http://www.nhs.uk ), the,digital ... well guide on women,s,health aged 18-39 aimed at ... lifestyle., Based on NHS accredited information, the ... with information about,walking to get healthy, looking after ...
... June 24 TransUnion announced today a ... cycle workflow and,financial analytics product suite -- ... Institute (ANI) Healthcare Financing Conference. Revenue,Manager is ... real time,patient eligibility for financial assistance at ...
... LOS ANGELES, June 24 Anti-Doping Research,Inc. (ADR), one ... performance-enhancing drugs in sport, is pleased to announce that ... "We,ve been up and running and fully-operational for a ... Officer of the organization. "But,now it,s all official and ...
... Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, a medical ... today, in an update for Company,shareholders, said its ... 31, 2008,totaled $32,300., Net income for the ... Company announced that patient billings from its four ...
... To, Implement Electronic Bill / Payment Solutions Before Minnesota,s ... ... and CONCORD, Calif., June 24 More than one,hundred auto insurance ... Mitchell Medical,s 2008 Industry,Conference held March 17-19 in Monterey, CA were ...
... in Generic Market Information Offers Newport Horizon ... ... SHANGHAI, China, June 24 /Xinhua-PRNewswire/ -- Thomson Reuters, the,world,s leading ... CPhI China 2008(1) the release of Newport,Horizon Premium, designed specifically ...
Cached Medicine News:Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 2Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 3Health News:TransUnion's Enhanced Revenue Manager(SM) Improves Patient Financial Assistance, Assessments and Hospital Productivity 4Health News:Leading Performance-Enhancing Drug Research Institute Anti-Doping Research (ADR) Establishes Nonprofit Status 2Health News:American HealthChoice CEO Dr. J.W. Stucki Provides Company Update 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 2Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 3Health News:2008 Mitchell Medical Industry Conference Previews 100 Percent Paperless Auto Medical Claim Solution 4Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 2Health News:Thomson Reuters Introduces a New Solution to Boost Competitive Advantage in China's Generics and API Market 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: